

ANTIGENICS INC /DE/  
Form S-8  
June 18, 2008

As filed with the Securities and Exchange Commission on June 18, 2008

REGISTRATION NO. 333

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Form S-8**

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

**Antigenics Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State or other jurisdiction of  
incorporation or organization)*

**162 Fifth Avenue, Suite 900, New York, NY 10010**

*(Address of principal executive offices, including zip code)*

**1999 EQUITY INCENTIVE PLAN, AS AMENDED**

*(Full title of the plan)*

**Garo H. Armen, Ph.D**

**06-1562417**  
*(I.R.S. Employer*

*Identification No.)*

Edgar Filing: ANTIGENICS INC /DE/ - Form S-8

**Antigenics Inc.**

**162 Fifth Avenue, Suite 900**

**New York, NY 10010**

**212-994-8200**

(Name, address and telephone number, including area code, of agent for service)

**Please send copies of all communications to:**

**Paul M. Kinsella**

**Ropes & Gray LLP**

**One International Place**

**Boston, MA 02110**

**617-951-7000**

**617-951-7050 (facsimile)**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller reporting company

**CALCULATION OF REGISTRATION FEE**

<b>Title of securities to be registered</b>	<b>Amount to be registered</b>	<b>Proposed maximum offering price per share(1)</b>	<b>Proposed maximum aggregate offering price(1)</b>	<b>Amount of registration fee</b>
Common Stock, \$0.01 par value per share	2,000,000 shares(2)	\$2.07	\$4,140,000	\$162.70

## Edgar Filing: ANTIGENICS INC /DE/ - Form S-8

- (1) Pursuant to Rules 457(c) and 457(h)(1) under the Securities Act of 1933, the proposed maximum offering price per share and the proposed maximum aggregate offering price for the shares have been calculated solely for the purpose of computing the registration fee on the basis of the average high and low prices of the Common Stock as reported on the NASDAQ Global Market on June 11, 2008 to be \$2.14 and \$2.00, respectively.
- (2) Pursuant to Rule 416(a) under the Securities Act of 1933, this registration statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions.

Explanatory Note

The Registrant increased the number of shares of the Registrant's Common Stock available for future issuance under the 1999 Equity Incentive Plan, as amended (the Plan) by two million shares so that a total of twelve million shares are now available under the Plan.

Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333-40442) filed with the Securities and Exchange Commission on June 29, 2000 and amended on June 11, 2003.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 18th day of June, 2008.

Antigenics Inc.

By: /s/ Garo H. Armen, Ph.D.  
Garo H. Armen, Ph.D.  
*Chief Executive Officer and  
Chairman of the Board*

POWER OF ATTORNEY

We, the undersigned officers and directors of Antigenics Inc., hereby severally constitute and appoint Garo Armen and Shalini Sharp, and each of them singly, our true and lawful attorneys-in-fact, with full power to them in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8 (including any post-effective amendments thereto), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities indicated on June 18, 2008:

<b>Signature</b>	<b>Title</b>
/s/ Garo H. Armen, Ph.D. Garo H. Armen, Ph.D.	Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)
/s/ Shalini Sharp Shalini Sharp	Vice President and Chief Financial Officer (Principal Financial Officer)
/s/ Christine M. Klaskin Christine M. Klaskin	Vice President, Finance (Principal Accounting Officer)
/s/ Tom Dechaene Tom Dechaene	Director
/s/ Brian Corvese Brian Corvese	Director
/s/ Margaret Eisen Margaret Eisen	Director
/s/ John Hatsopoulos John Hatsopoulos	Director
/s/ Wadiah Jordan Wadiah Jordan	Director
/s/ Hyam I. Levitsky, MD Hyam I. Levitsky, MD	Director

Edgar Filing: ANTIGENICS INC /DE/ - Form S-8

/s/ Peter Thornton  
Peter Thornton

Director

/s/ Timothy R. Wright  
Timothy R. Wright

Director

**EXHIBIT INDEX**

The following is a list of exhibits filed as part of this registration statement.

<i>Exhibit</i>	<i>Description</i>	<i>Location</i>
4.1	Amended and Restated Certificate of Incorporation of Antigenics Inc. Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) dated June 10, 2002 and incorporated herein by reference.	
4.2	Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Antigenics Inc. Filed as Exhibit 3.1 to our Current Report on Form 8-K (File No. 000-29089) dated June 11, 2007 and incorporated herein by reference.	
4.3	Second Amended and Restated By-laws of Antigenics Inc. Filed as Exhibit 3.2 to our Current Report on Form 8-K (File No. 000-29089) dated December 17, 2007 and incorporated herein by reference.	
5.1	Opinion of Ropes & Gray LLP dated June 16, 2008.	*
23.1	Consent of Ropes & Gray LLP (included in Opinion filed as Exhibit 5.1).	*
23.2	Consent of KPMG LLP, Independent Registered Public Accounting Firm.	*
24.4	Power of Attorney.	Signature Page
99.1	1999 Equity Incentive Plan, as amended. Filed as Exhibit 10.1 to our Current Report on Form 8-K (File No. 000-29089) dated June 4, 2008 and incorporated herein by reference.	

\* Filed herewith.